Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could zapping a different brain region tame epilepsy?

NCT ID NCT04692701

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This pilot study tests deep brain stimulation (DBS) of the medial pulvinar, a new target in the brain, for people with drug-resistant epilepsy who have not improved with other treatments. Twelve adults aged 18 to 60 will receive the stimulation and track their seizures for 12 months. The goal is to see if this approach can reduce seizure frequency and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain stimulation device targeting the medial pulvinar
What this could lead to
If successful, this could offer a new treatment option for people with drug-resistant epilepsy who have not responded to other therapies.
What could go wrong
This is a very small pilot study with only 12 participants, so results may not apply widely. The approach is still experimental and may not reduce seizures significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Jan 2021

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: between 18 and 60 years old * Focal or multifocal drug-resistant epilepsy not operable or failure of epilepsy surgery * Vagal nerve stimulation failure (after at least 1 year of treatment or stopped early for worsening seizures) * Either patients with epilepsy whose characteristics suggest that it may respond better to stimulation of the pulvinar than the anterior thalamic nucleus stimulation (i.e. posterior quadrant epilepsy, motor/premotor epilepsy, operculo-insular epilepsy, temporal plus epilepsy, lateral temporal epilepsy) or/and patients with previous anterior thalamic nucleus stimulation failure (after 2 years of treatment or stopped early for worsening seizures) * Number of seizures \> 4 / month during the baseline (3 months) and before the V0 for at least 3 months * Total IQ \> 55 * Give written consent to the study after receiving clear information * Be a beneficiary or affiliated to a health insurance plan * For women of childbearing potential, a pregnancy test must be negative before inclusion. Exclusion Criteria: * Difficulty to read or understand the French language, or inability to understand the information regarding the study. * Generalized epilepsy * Presenting contraindication to MRI, a serious intercurrent pathology, a progressive brain tumor. * Pregnancy or breastfeeding * Present a history of attempted suicide in the 6 months prior to inclusion or a score ≥ 2 in item 10 of the Montgomery and Asberg Depression Scale (MADRS). * Present a surgical or anaesthetic contraindication. * Require long-term anticoagulant or platelet aggregation therapy. * Hereditary bleeding disorders of coagulation * Non obliterated AVM * History of Herpes virus brain infection * Total IQ below 55. * Patients with less than 4 seizures a month * To be hospitalized under duress (HO / HDT) * Major under guardianship or curatorship * Person deprived of liberty by judicial decision * Patient currently participating in another clinical trial or having participated in a clinical trial in the month prior to inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service de Neurologie

    Nice, 13385, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.